Theradiag announces its results for the first half of 2021

0

Enter Wall Street with StreetInsider Premium. Claim your 1-week free trial here.


Theradiag close to equilibrium

  • Thanks to a clear improvement in net income before non-recurring items: + 84.3%
  • While maintaining its strategy of investing in R&D and the United States to fuel future growth

Theradiag will hold a videoconference today at 5:45 p.m. (CEST).

To participate, please register via the following link:

https://us02web.zoom.us/webinar/register/WN_X36ssiYPT6y3Ymc5eFQ_qw

CROISSY-BEAUBOURG, France – (BUSINESS WIRE) – Regulatory News:

THERADIAG (Paris: ALTER) (ISIN: FR0004197747, Ticker: ALTER), company specializing in in vitro diagnostics and Theranostics, today announces its half-year results as of June 30, 2021, as approved by the Board of Directors on September 16, 2021.

H1 2021 results

In thousands of euros

S1 2021

H1 2020

% cash

Returned

5 482

4 871

+ 12.5%

of which: Theranostic

2,766

2410

+ 14.7%

of which: IVD

2,716

2,461

+ 10.4%

Operating profit / (loss)

(178)

(423)

+ 57.9%

Profit / (loss) before tax and non-recurring items

(206)

(358)

+ 42.4%

Net income / (loss) before non-recurring items

(23)

(146)

+ 84.3%

Non-recurring items

(68)

(83)

+ 18.0%

Net income / (loss)

(92)

(229)

+ 59.8%

Bertrand de Castelnau, CEO of Theradiag, commented : “For the past year, we have been reaping the benefits of the efforts made to control our operating costs and our marketing strategy. Indeed, the effectiveness of our strategic refocusing is demonstrated by the significant improvement in all our financial indicators in the first half of the year despite an economic and public health context which remains uncertain. Based on sustained activity for our innovative solutions and a healthier cost structure, we intend to accelerate Theradiag’s development by implementing a strategic plan in line with our growth ambitions in our target markets. The follow-up of biotherapies is a large global market, and the next semesters look promising for Theradiag”.

The solid improvement in these results demonstrates the success of the Company’s structuring phase initiated a few semesters ago. They also materialize the work of the Theradiag teams, which I would like to congratulate. We must now accelerate our growth in our preferred markets, and in particular in the Theranostics market“added President of the council Pierre Morgon.

Turnover up 12.5% ​​despite an uncertain health situation

As of June 30, 2021, Theradiag achieved a turnover of 5.5 million euros, compared to 4.9 million euros in the first half of 2020, despite an economic and public health context characterized by persistent difficulties of access to hospital care for patients undergoing immunotherapy in all countries.

Theranostic activity continued to grow with an increase of + 14.7% in H1, driven in particular by the dynamism of sales of the automated i-Track10. Marked by strong growth for several semesters, the Theranostics activity represents for the first time the bulk of Theradiag’s sales over the first 6 months of 2021.

The Theranostics activity carried out in the United States in partnership with HalioDX generated a turnover of 0.5 million euros, in line with the Company’s development plan, and is thus up 33.6% . In exports, the Company maintained a sustained level of activity, with sales up 27.4% to € 1.3 million. Penalized by maintaining white plans emergency plans in hospitals, activity in France slowed down slightly, down 5.2% compared to the first half of 2020.

IVD (In vitro Diagnosis) activity generated growth of + 10.4%, with revenue of 2.7 million euros at June 30, 2021.

Substantial improvement in financial indicators thanks to better control of operating costs and a refocusing of Theradiag’s strategy on its fundamentals

After strong growth in the second half of 2020, the operating loss continued to decline significantly, by 57.9%, in the first half of 2021. This improvement illustrates Theradiag’s ability to develop commercially while continuing to manage strict operating costs. At the same time, as in previous semesters, Theradiag stepped up its investments in R&D and its commercial development in the United States in order to strengthen its leadership position in the monitoring of biotherapies in France and abroad. In addition, the Company has expanded its Quality team to be able to comply with the requirements of the new European Union directive on in vitro diagnostic medical devices (DRIV).

In the same vein, net income before recurring items improved by 84.3% compared to the same period in 2020. It is now close to breakeven, representing -0.4% of sales.

Comprehensive net income, including non-recurring items, improved by 59.8% to – € 92,000 as of June 30, 2021, compared to – € 229,000 as of June 30, 2020.

Cash flow and financial structure

As of June 30, 2021, Theradiag had € 1.4 million in net free cash, compared to € 3.5 million as of December 31, 2020. This difference results from cash mismatches, now resolved, for € 0.5 million, while investments in R&D and international development are in line with Theradiag’s strategic plan.

To finance its growth strategy in the biotherapies monitoring market while maintaining a solid financial structure, Theradiag does not exclude the possibility of raising additional funds depending on market conditions and the progress of its strategic plan.

Reminder of the main highlights of H1 2021

  • January 2021: CE marking of the four new i-Tracker® test kits: i-Tracker® Vedolizumab, i-Tracker® Anti-Vedolizumab, i-Tracker® Ustekinumab and i-Tracker® Anti-Ustekinumab, on the originator molecules and biosimilars
  • January 2021: Signature of a contract for the supply of quality control reagents to Orgentec, a specialist in in vitro diagnostics, particularly in the field of autoimmunity, infectious diseases and molecular biology
  • May 2021: Participation in Humabdiag, a large-scale research project carried out with the University of Tours targeting the bioproduction of monoclonal antibodies dedicated in particular to Theradiag and to the entire biotherapies market.

About Theradiag

Theradiag is the market leader in the monitoring of biotherapies. Capitalizing on its expertise in the diagnostics market, the Company develops, manufactures and markets innovative products in vitro diagnostic tests (IVD) for over 30 years.

Theradiag was the pioneer of “theranostic” tests (combining therapy and diagnosis) which measure the effectiveness of biotherapy in the treatment of chronic inflammatory diseases. Beyond the simple diagnosis, Theranostics aims to help clinicians set up a “personalized treatment” for each patient. This method promotes individualization of treatment, evaluation of its effectiveness and prevention of drug resistance. To meet this challenge, Theradiag develops and markets the TRACKER® range, CE marked, a global solution of inestimable medical value.

The Company is based in Marne-la-Vallée, near Paris, is present in more than 70 countries and employs more than 60 people. In 2020, the Company achieved sales of 10.4 million euros. The Theradiag share is listed on Euronext Growth Paris (ISIN: FR0004197747) and is eligible for PEA-PME.

For more information about Theradiag, please visit our website: https://www.theradiag.com/

Theradiag

Bertrand de Castelnau

CEO / Managing Director

Phone. : +33 (0) 1 64 62 10 12

[email protected]

NewCap

Financial Communication & Investor Relations

Pierre Laurent

Quentin Massé

Phone. : +33 (0) 1 44 71 94 94

[email protected]

NewCap

Media relations

Nicolas merigeau

Phone. : +33 (0) 1 44 71 94 98

[email protected]

Source: Théradiag


Source link

Share.

About Author

Comments are closed.